BEAUTIFUL Fast Facts
BEAUTIFUL is the first trial assessing the morbidity-mortality benefits of the pure heart rate–lowering agent Ivabradine (Procoralan®)*.
BEAUTIFUL is evaluating in coronary artery disease patients with left ventricular dysfunction, the benefits of Ivabradine beyond current preventive therapy in terms of:
- Cardiovascular mortality
- Hospital admission for acute myocardial infarction
- Hospital admission for new-onset or worsening heart failure
BEAUTIFUL will provide unique information on the importance of elevated heart rate in cardiovascular disease and the benefits of an interventional pharmacological therapy that exclusively reduces heart rate. 10 917 patients at 781 centers in 33 different countries are participating in the BEAUTIFUL study. The results of the BEAUTIFUL study will be presented in September 2008 at the ESC congress in Munich, Germany.
References
1. Fox K, Ferrari R, Tendera M, Steg PG, Ford I; on behalf of the BEAUTIFUL Steering Committee. Rationale and design of a randomised, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Am Heart J 2006;152:860-866.
2. The BEAUTIFUL Study Group.The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction—baseline characteristics of the study population. Cardiology. 2008;110:271-282.